TRAP1 and non-human animal disease: Consistently, combined neutralization of such proangiogenic factors has better efficacy than VEGF monotherapy in animal disease models,[40] and a bispecific antibody drug, faricimab, has recently been approved for the treatment of ocular diseases.[21b] These considerations support the proposition that a TRAP1 inhibition strategy could be effective for the treatment of ischemic retinopathies, which would inactivate the upstream master regulator HIF1α to simultaneously block pathological up‐regulation of multiple angiogenic regulators.